Kymera reports FY2025 net loss $311M; cash $1.6B; STAT6 and IRF5 trials advancing

Kymera Therapeutics, Inc.

2025-FY EPS reported -$3.69 revenue$39,211,000

Cash and investments of $1.6B as of Dec 31, 2025, providing runway into 2029.
KT-621 (STAT6) Phase 2b in atopic dermatitis (enrollment ongoing) and asthma (dosing started); data expected mid- and late-2027.
KT-579 (IRF5) Phase 1 healthy volunteer trial dosed; data expected in 2H26.
Appointed Dr. Neil Graham as Chief Development Officer; he led dupilumab development at Regeneron.
FY2025 collaboration revenue $39.2M, R&D expense $316.6M, net loss $311.4M (vs. $223.9M in FY2024).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.